Acadia reported higher third-quarter revenue and raised DAYBUE guidance, while its Phase II RADIANT study narrowly missed statistical significance on the primary endpoint. Shares fell 1.1% after earnings, a roughly flat reaction.
- Total revenue was $342 million, up 22% year over year on an adjusted basis.
- DAYBUE sales reached a record $140 million, up 39%; management raised 2026 DAYBUE guidance.
- NUPLAZID sales were $202 million, up 12% on an adjusted basis, with growth driven largely by patient demand through volume.
- RADIANT’s Phase II portion narrowly missed statistical significance on its primary endpoint; Acadia plans to focus the Phase III program on the 60-milligram dose.
- Acadia expects ILLUMERA Phase II results in LBD psychosis in the fourth quarter of 2027, while an additional NORLIGHT readout is now expected in the second half of 2027.
Community Discussion